Acadia Pharmaceuticals | ACAD - Operating Profit

Stock Price
26.14
Daily Change
1.01 4.02%
Monthly
-0.04%
Yearly
41.22%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $35.76M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Pfizer USD 652M 3.67B Sep/2025
Prothena USD -39.76M 12.25M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025